Beta Drugs Ltd
Beta Drugs Q2 Results 2026 (FY27): Revenue ₹31 Cr, EBITDA margin 23.2%
Q2 FY27 investor presentation: what the company reported on revenue, capex and fundraising.
Based on Beta Drugs Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue progression (H1 FY25 to H1 FY27): - H1 FY25: ₹180 Crs - H1 FY26: ₹204 Crs (+13.3% YoY from H1 FY25) - H1 FY27: ₹263 Crs (+28.9% YoY from H1 FY26, +46.1% from H1 FY25) - Sales and segment EBITDA Margin: 23.2% in H1 FY27, up slightly from 23.1% in H1 FY26 (page 22).
From Beta Drugs Ltd's Q2 FY27 earnings-call transcript · updated 22 Oct 2026.
Revenue & Sales Performance
- Revenue progression (H1 FY25 to H1 FY27):
- H1 FY25: ₹180 Crs
- H1 FY26: ₹204 Crs (+13.3% YoY from H1 FY25)
- H1 FY27: ₹263 Crs (+28.9% YoY from H1 FY26, +46.1% from H1 FY25)
- Sales and segment highlights for H1 FY27:
- Branded: ₹71 Crs (17% growth YoY)
- Exports: ₹43 Crs
- CMO Business: ₹95 Crs (21% growth YoY)
- Nivian brand sales: ₹31 Crs (75% YoY growth)
- Other: ₹23 Crs
- Volume/Capacity:
- API business grew ~30% in volume/scale
- Capacity expansions with ₹26 Crs invested up to H1 FY27 in API and backward integration
- Financial metrics:
- Gross margin improved from 51.4% to 56.2% (H1 FY26 to H1 FY27)
- EBITDA margin steady around 23.2% (H1 FY27)
- Outlook:
- Expansion of API capacity expected in Q4 FY27
2 more points from Beta Drugs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Capital Expenditure Plans
- Invested ~26 Crs up to H1 FY27 towards API capacity expansion and backward integration (Page 19).
- Additional investment of ~35 Crs towards expansion of API capacity and backward integration (Page 11).
- New API capacity expected to go onstream in Q4 FY27 (Page 10).
- Large installed manufacturing capacities at Beta Drugs Ltd. and Adley facilities, including:
- KSM capacity: 10 MTPA
- API capacity: 9 MTPA (Page 6).
2 more points from Beta Drugs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
- The Balance Sheet on page 21 shows Borrowings (long term & short term) changed as follows:
- H1’25: Rs 19 Cr
- H1’26: Rs 146 Cr
- H1’27: Rs 49 Cr
- Equity Share Capital increased significantly from Rs 181 Cr (H1’25) to Rs 475 Cr (H1’27).
- Total liabilities increased from Rs 295 Cr (H1’25) to Rs 656 Cr (H1’27).
2 more points from Beta Drugs Ltd's call on fundraising
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Beta Drugs Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY23 earnings call →
- Q2 FY23 earnings call →
- Q4 FY22 earnings call →
- Q2 FY22 earnings call →
- Q4 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
- Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
- Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
- Solara Active (Q2 FY27)
417.34 Crores, up from Rs. Key results statement takeaways from Solara Active Pharma Sciences Ltd's Q2 FY27 results statement — and how it ranks against sector
Arthneeti Pro · Annual
Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Beta Drugs Ltd Q2 FY27 results?
Revenue progression (H1 FY25 to H1 FY27): - H1 FY25: ₹180 Crs - H1 FY26: ₹204 Crs (+13.3% YoY from H1 FY25) - H1 FY27: ₹263 Crs (+28.9% YoY from H1 FY26, +46.1% from H1 FY25) - Sales and segment EBITDA Margin: 23.2% in H1 FY27, up slightly from 23.1% in H1 FY26 (page 22).
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹1,845 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Invested ~26 Crs up to H1 FY27 towards API capacity expansion and backward integration (Page 19). - Additional investment of ~35 Crs towards expansion of API capacity and backward integration (Page 11). - New API capacity expected to go onstream in Q4 FY27 (Page 10).
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.